USANA Health Sciences (NYSE:USNA) PT Lowered to $46.00

USANA Health Sciences (NYSE:USNA - Free Report) had its price objective reduced by DA Davidson from $48.00 to $46.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock.

Separately, StockNews.com upgraded USANA Health Sciences from a buy rating to a strong-buy rating in a report on Friday, January 12th.

USANA Health Sciences Stock Performance

Shares of NYSE:USNA traded up $0.12 during midday trading on Tuesday, reaching $44.74. The company had a trading volume of 61,789 shares, compared to its average volume of 81,501. The company has a fifty day simple moving average of $46.54 and a two-hundred day simple moving average of $48.15. The firm has a market cap of $858.91 million, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 1.38 and a beta of 0.94. USANA Health Sciences has a 1-year low of $41.45 and a 1-year high of $69.60.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The business had revenue of $221.08 million for the quarter, compared to the consensus estimate of $206.70 million. Analysts expect that USANA Health Sciences will post 2.75 EPS for the current year.

Insider Buying and Selling

In related news, insider Daniel A. Macuga sold 3,791 shares of the business's stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total value of $178,707.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider David Mulham Mulham sold 4,311 shares of the business's stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $47.76, for a total transaction of $205,893.36. Following the completion of the transaction, the insider now owns 7,825 shares of the company's stock, valued at approximately $373,722. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel A. Macuga sold 3,791 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total value of $178,707.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,286 shares of company stock worth $1,634,010. Corporate insiders own 0.33% of the company's stock.

Institutional Trading of USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of USNA. Pzena Investment Management LLC grew its holdings in shares of USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company's stock worth $38,089,000 after purchasing an additional 23,729 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in USANA Health Sciences by 18.1% in the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company's stock valued at $1,883,000 after buying an additional 5,952 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of USANA Health Sciences by 58.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company's stock worth $3,987,000 after acquiring an additional 30,485 shares during the period. DGS Capital Management LLC boosted its position in shares of USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company's stock valued at $352,000 after acquiring an additional 2,773 shares in the last quarter. Finally, First Hawaiian Bank increased its stake in USANA Health Sciences by 22.3% in the first quarter. First Hawaiian Bank now owns 9,089 shares of the company's stock valued at $441,000 after acquiring an additional 1,656 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.